Derma Sciences, Inc.
US Elections Calendar ~ Pervez Musharraf ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / March 24, 2008
Derma Sciences to Report 2007 Fourth Quarter and Year-End Results on April 1, 2008

Top News

Andhra Pradesh Intermediate Results 2008

Chandrababu interacts with farmers who lost their crop in Guntur market fire

CEC to visit Dharwar to review poll preparations

Indian youth groups in Malaysia seek funds for education

Scooter knocks Madge off top of British album charts

International conference on The New Business Laws Of India culminates into a grand debate

The Great Khali heads for hometown Himachal Pradesh

Intensive farming does well to conserve biodiversity

Using marijuana to battle the blues only worsens teens depression

Derma Sciences to Report 2007 Fourth Quarter and Year-End Results on April 1, 2008

PRINCETON, N.J., March 24 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTCBB:DSCI), provider of advanced wound care products, announced today that it will report its fourth quarter and year-end 2007 results on April 1, 2008. The Company will hold a conference call that same day to discuss the results at 11:00 am EDT. Interested parties should call 800-510-0219 (domestic) or 617-614-3451 (international), with passcode 77274977 to access the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=1805202

For those who are unavailable to listen to the live broadcast, a replay will be available through April 8, 2008 and can be accessed by dialing 888-286-8010 (domestic), and 617-801-6888 (international). The pass code is 71798685.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

     Contact:  Derma Sciences, Inc.        Allen & Caron Inc
               Edward J. Quilty            Rudy Barrio (US Investors)
               Chairman and CEO            r.barrio@allencaron.com
               equilty@dermasciences.com
               (609) 514-4744              Brian Kennedy (media)
                                           brian@allencaron.com
                                           (212) 691-8087

SOURCE Derma Sciences, Inc.

International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.

International Business News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Beijing Komoxo Mobile Software Licenses Patents From Microsoft
PR Newswire

The Conference Board(R) Australia Business Cycle Indicators(SM)
PR Newswire

Martin Froggatt to Succeed Paul Barry as President of Europe Express
PR Newswire

Boeing, Lion Air Celebrate 10th 737-900ER Delivery
PR Newswire

International Medical News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Terumo, Global Medical Technology Company, Opens Office in Switzerland
PR Newswire

HeartWare Appoints David R. Hathaway, M.D. Chief Medical Officer
PR Newswire

Hoya Announces Fourth Quarter and FY2007 Financial Results
PR Newswire

Lupin Announces Launch of Suprax(R) 400mg Tablets
PR Newswire

International Health News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Death Toll From Recalled Chinese Heparin Continues to Rise; Tainted Heparin Still in Circulation
PR Newswire

Hoya Announces Fourth Quarter and FY2007 Financial Results
PR Newswire

Lupin Announces Launch of Suprax(R) 400mg Tablets
PR Newswire

Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
PR Newswire